|
WO2021046409A1
|
|
Materials and methods for blood plasma preparations
|
|
US2021046120A1
|
|
Thrombosomes as an anticoagulant reversal agent
|
|
US2021046121A1
|
|
Thrombosomes as an antiplatelet agent reversal agent
|
|
WO2021011857A1
|
|
Use of platelets in treating infections
|
|
WO2020227149A1
|
|
Materials and methods for producing blood products
|
|
WO2020186193A1
|
|
Canine blood platelet preparations
|
|
US2020206143A1
|
|
Platelets loaded with anti-cancer agents
|
|
WO2020112963A1
|
|
Platelets as delivery agents
|
|
CA3112455A1
|
|
Blood plasma-containing compositions
|
|
AU2019310587A1
|
|
Cryopreserved platelet compositions and methods for making
|
|
CA3074712A1
|
|
Canine blood platelet preparations
|
|
TW202000213A
|
|
Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
|
|
WO2017123539A1
|
|
Nucleated cell preservation by lyophilization
|
|
WO2018106250A1
|
|
Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
|
|
CA3005615A1
|
|
Products and methods using a platelet-derived hemostatic agent for controlling bleeding and improving healing
|
|
BR112017026660A2
|
|
composition and kit for treating fluid loss causing hypotension and / or hypovolemia
|
|
CA3005311A1
|
|
Products and devices for controlling and stopping bleeding and methods of using
|
|
US2006034809A1
|
|
Use of stabilized platelets as hemostatic agent
|
